NASDAQ · Biotechnology

Aardvark Therapeutics, Inc. (AARD) Stock

$4.76 +1.06% NASDAQ: AARD Healthcare

Valuation

MetricValue
Price$4.76
Market Cap$104.17M
P/E Ratio-1.55
P/B Ratio1.46
P/S Ratio0.00
EPS (TTM)$-2.64
52-Week High$17.94
52-Week Low$3.35
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-71.54%
ROA-85.80%
ROCE-98.51%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.01
Current Ratio10.18

Annual Financials (USD)

Metric2022202320242025
Revenue$0$0$0$0
Operating Profit$-11.0M$-7.0M$-23.0M$-63.0M
Net Profit$-14.0M$-7.0M$-21.0M$-58.0M
EPS$-0.63$-0.34$-0.95$-2.64
Op Margin————

Balance Sheet (USD)

Metric2022202320242025
Total Assets$17.0M$11.0M$78.0M$117.0M
Total Liabilities$45.0M$45.0M$132.0M$11.0M
Cash$16.0M$10.0M$62.0M$47.0M
Borrowings$0$0$1.0M$0

Latest News

Several Insiders Invested In Aardvark Therapeutics Flagging Positive News Simply Wall St. · May 28, 2026 Sector Update: Healthcare Stocks Decline Late Afternoon MT Newswires · May 15, 2026 Top Midday Decliners MT Newswires · May 15, 2026 Sector Update: Healthcare Stocks Softer Friday Afternoon MT Newswires · May 15, 2026 Sector Update: Healthcare MT Newswires · May 15, 2026

Cash Flow (USD)

Metric2022202320242025
Operating Cash Flow$-11.0M$-6.0M$-18.0M$-54.0M
Investing Cash Flow$-1.0M$0$-12.0M$-50.0M
Financing Cash Flow$1.0M$0$-3.0M$0
Net Cash Flow$-11.0M$-6.0M$52.0M$-15.0M
Free Cash Flow$-11.0M$-6.0M$-18.0M$-54.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.03
EV / EBITDA-0.52
FCF Yield-63.56%
Quick Ratio12.63
Interest Coverage0.00
Return 1Y-48.31%
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $336.64 -1.11% 38.93 $4.94T 0.32%
MSFTMicrosoft Corporation $535.07 +2.38% 28.68 $3.97T 0.76%
GOOGLAlphabet Inc. $351.66 +0.97% 16.94 $4.26T 0.26%
AMZNAmazon.com, Inc. $262.43 +3.29% 19.82 $2.82T 0.00%
METAMeta Platforms, Inc. $718.67 -0.31% 27.93 $1.83T 0.28%

About Aardvark Therapeutics, Inc.

Aardvark Therapeutics, Inc. is led by CEO Tien-Li Lee, employs 22 people, headquartered in US, publicly traded since 2025.

Aardvark Therapeutics, Inc. (AARD) stock trades at $4.76 with a market capitalization of $104.17M. The stock is valued at a price-to-earnings (P/E) ratio of -1.55, price-to-book of 1.46, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $3.35 and $17.94, and currently trades 73.5% below its 52-week high.

On profitability, Aardvark Therapeutics, Inc. generates a return on equity (ROE) of -71.54%, return on capital employed of -98.51%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides